Evolus, Inc. (NASDAQ:EOLS) Short Interest Down 6.6% in March

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a drop of 6.6% from the March 15th total of 4,980,000 shares. Based on an average trading volume of 657,700 shares, the short-interest ratio is currently 7.1 days. Approximately 9.8% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on EOLS shares. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Friday, March 1st. Barclays upgraded Evolus from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $10.00 to $16.00 in a research report on Monday, January 29th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 10th.

Insider Activity

In other news, CFO Sandra Beaver sold 5,672 shares of Evolus stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the sale, the chief financial officer now directly owns 154,201 shares in the company, valued at approximately $2,146,477.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Sandra Beaver sold 5,672 shares of Evolus stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the sale, the chief financial officer now directly owns 154,201 shares in the company, valued at approximately $2,146,477.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rui Avelar sold 27,603 shares of Evolus stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $384,233.76. Following the transaction, the insider now owns 372,288 shares of the company's stock, valued at $5,182,248.96. The disclosure for this sale can be found here. In the last three months, insiders sold 60,969 shares of company stock worth $831,005. Company insiders own 5.40% of the company's stock.

Institutional Trading of Evolus

Several institutional investors have recently made changes to their positions in the stock. Stonepine Capital Management LLC grew its stake in shares of Evolus by 3.0% during the 4th quarter. Stonepine Capital Management LLC now owns 5,333,004 shares of the company's stock valued at $56,157,000 after buying an additional 154,000 shares during the period. Perceptive Advisors LLC grew its stake in shares of Evolus by 166.8% during the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company's stock valued at $41,735,000 after buying an additional 2,477,623 shares during the period. BlackRock Inc. grew its stake in shares of Evolus by 22.7% during the 2nd quarter. BlackRock Inc. now owns 2,995,386 shares of the company's stock valued at $21,776,000 after buying an additional 554,417 shares during the period. Vanguard Group Inc. grew its stake in shares of Evolus by 9.1% during the 4th quarter. Vanguard Group Inc. now owns 2,943,512 shares of the company's stock valued at $30,995,000 after buying an additional 244,865 shares during the period. Finally, Nantahala Capital Management LLC grew its stake in shares of Evolus by 591.1% during the 4th quarter. Nantahala Capital Management LLC now owns 2,910,849 shares of the company's stock valued at $30,651,000 after buying an additional 2,489,629 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Price Performance

EOLS traded up $0.16 during trading on Tuesday, hitting $12.05. The company's stock had a trading volume of 497,647 shares, compared to its average volume of 638,202. The firm's 50 day moving average price is $13.70 and its 200-day moving average price is $11.13. The stock has a market cap of $698.18 million, a PE ratio of -11.06 and a beta of 1.45. Evolus has a twelve month low of $7.07 and a twelve month high of $15.43.

Evolus (NASDAQ:EOLS - Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. Equities analysts anticipate that Evolus will post -0.51 earnings per share for the current year.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.